

SECTION 1: IDENTIFICATION

1.1. Product Identifier

Product Form: Mixture

Product Name: Bumetanide Injection USP

1.2. Intended Use of the Product

Bumetanide Injection USP is indicated for treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

1.3. Name, Address, and Telephone of the Responsible Party

Manufacturer

Gland Pharma Limited
 UNIT-II, Plot 42 to 52, Sy.No.166,
 171,172 & 177, Phase-III, TSIC,
 Pashamylaram (Village),
 Patancheru (Mandal), Sangareddy (District),
 Telangana state, INDIA
 +91-8455- 222000

Distributor

Fresenius Kabi USA, LLC
 Three Corporate Drive
 Lake Zurich, IL 60047 USA
 General Phone Number: (847) 550-2300
 Customer Service Phone Number: (888) 386-1300
 Health Issues Information: (800) 551-7176
<http://www.fresenius-kabi.com/us/>

1.4. Emergency Telephone Number

Emergency Number : ChemTel LLC
 (800)255-3924 (North America)
 +1 (813)248-0585 (International)

SECTION 2: HAZARDS IDENTIFICATION

2.1. Classification of the Substance or Mixture

GHS-US/CA Classification

Not classified

2.2. Label Elements

GHS-US/CA Labeling

No labeling applicable according to 29 CFR 1910.1200 and the Hazardous Products Regulations (HPR) SOR/2015-17.

2.3. Other Hazards

Exposure may aggravate pre-existing eye, skin, or respiratory conditions.

2.4. Unknown Acute Toxicity (GHS-US/CA)

No additional information available

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1. Substance

Not applicable

3.2. Mixture

Name	Synonyms	Product Identifier	% *	GHS Ingredient Classification
Benzyl alcohol	Benzenecarbinol / Benzenemethanol / Methanol, phenyl- / Phenylmethanol / Phenylmethyl alcohol / BENZYL ALCOHOL / .alpha.-Hydroxytoluene / Benzylalcohol	(CAS-No.) 100-51-6	1	Flam. Liq. 4, H227 Acute Tox. 4 (Oral), H302

Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

				Acute Tox. 4 (Inhalation:dust,mist), H332 Eye Irrit. 2A, H319 Aquatic Acute 2, H401
Bumetanide	Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- / Benzoic acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl- / bumetanide	(CAS-No.) 28395-03-1	0.025	Not classified

HFull text of H-statements: see section 16

*Percentages are listed in weight by weight percentage (w/w%) for liquid and solid ingredients. Gas ingredients are listed in volume by volume percentage (v/v%). The actual concentration of ingredient(s) is withheld as a trade secret in accordance with the Hazardous Products Regulations (HPR) SOR/2015-17 and 29 CFR 1910.1200.

SECTION 4: FIRST AID MEASURES

4.1. Description of First-aid Measures

General: Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible). In the event of accidental injection, immediately call a poison center or seek medical advice.

Inhalation: When symptoms occur: go into open air and ventilate suspected area. Obtain medical attention if breathing difficulty persists.

Skin Contact: Remove contaminated clothing. Wash with plenty of soap and water. Obtain medical attention if irritation develops or persists.

Eye Contact: Rinse cautiously with water for at least 5 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Obtain medical attention if irritation develops or persists.

Ingestion: Rinse mouth. Do NOT induce vomiting. Obtain medical attention.

4.2. Most Important Symptoms and Effects Both Acute and Delayed

General: Not expected to present a significant hazard under anticipated conditions of normal use.

Inhalation: Prolonged exposure may cause irritation.

Skin Contact: Prolonged exposure may cause skin irritation.

Eye Contact: May cause slight irritation to eyes.

Ingestion: Ingestion may cause adverse effects.

Chronic Symptoms: None expected under normal conditions of use.

4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If exposed or concerned, get medical advice and attention. If medical advice is needed, have product container or label at hand.

Note to physician: Product is a loop diuretic and will exert this action when accidentally swallowed in addition to accidental injections. Appropriate treatment, especially when accidentally injected, may require maintenance of electrolyte balance and fluid volume.

SECTION 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing Media

Suitable Extinguishing Media: Not flammable. Use extinguishing media appropriate for surrounding fire.

Unsuitable Extinguishing Media: None known.

5.2. Special Hazards Arising From the Substance or Mixture

Fire Hazard: Product is not flammable.

Explosion Hazard: Product is not explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

5.3. Advice for Firefighters

Precautionary Measures Fire: Exercise caution when fighting any chemical fire.

Firefighting Instructions: Use water spray or fog for cooling exposed containers.

Protection During Firefighting: Do not enter fire area without proper protective equipment, including respiratory protection.

Hazardous Combustion Products: None known.

5.4. Reference to Other Sections

Refer to Section 9 for flammability properties.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal Precautions, Protective Equipment and Emergency Procedures

General Measures: Avoid prolonged contact with eyes, skin and clothing. Avoid breathing (vapor, mist, spray). If product is biologically contaminated, follow all institutional protocols concerning the potential release of pathogens.

Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

6.1.1. For Non-Emergency Personnel

Protective Equipment: Use appropriate personal protective equipment (PPE).

Emergency Procedures: Evacuate unnecessary personnel.

6.1.2. For Emergency Personnel

Protective Equipment: Equip cleanup crew with proper protection.

Emergency Procedures: Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

Ventilate area.

6.2. Environmental Precautions

Prevent entry to sewers and public waters.

6.3. Methods and Materials for Containment and Cleaning Up

For Containment: Contain any spills with dikes or absorbents to prevent migration and entry into sewers or streams.

Methods for Cleaning Up: Clean up spills immediately and dispose of waste safely. Absorb and/or contain spill with inert material, then place in suitable container. Contact competent authorities after a spill.

6.4. Reference to Other Sections

See Section 8 for exposure controls and personal protection and Section 13 for disposal considerations.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for Safe Handling

Additional Hazards When Processed: Accidental injection may cause pain and swelling at the injection site. Sharps should be handled appropriately to minimize risk of accidents.

Precautions for Safe Handling: Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Avoid prolonged contact with eyes, skin and clothing. Avoid breathing vapors, mist, spray.

Hygiene Measures: Handle in accordance with good industrial hygiene and safety procedures.

7.2. Conditions for Safe Storage, Including Any Incompatibilities

Technical Measures: Comply with applicable regulations. Keep cool. Protect from sunlight.

Storage Conditions: Keep container closed when not in use. Store in a dry, cool place. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials.

Incompatible Materials: Strong acids, strong bases, strong oxidizers.

Storage Temperature: 20 – 25 °C (68 – 77 °F). Excursions permitted to 15 – 30 °C (59 – 86 °F). Protect from light.

7.3. Specific End Use(s)

Bumetanide Injection USP is indicated for treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), AIHA (WEEL), NIOSH (REL), OSHA (PEL), or Canadian provincial governments.

Benzyl alcohol (100-51-6)		
USA AIHA	WEEL TWA [ppm]	10 ppm

8.2. Exposure Controls

Appropriate Engineering Controls: Suitable eye/body wash equipment should be available in the vicinity of any potential exposure. Ensure adequate ventilation, especially in confined areas. Ensure all national/local regulations are observed.

Personal Protective Equipment: Gloves. Protective clothing. Safety glasses.



Materials for Protective Clothing: Chemically resistant materials and fabrics.

Hand Protection: Wear protective gloves.

Eye and Face Protection: Safety glasses with side-shields.

Skin and Body Protection: Wear suitable protective clothing.

Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

Respiratory Protection: If exposure limits are exceeded or irritation is experienced, approved respiratory protection should be worn. In case of inadequate ventilation, oxygen deficient atmosphere, or where exposure levels are not known wear approved respiratory protection.

Other Information: When using, do not eat, drink or smoke.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on Basic Physical and Chemical Properties

Physical State	: Liquid
Appearance	: Clear, colorless to slightly yellow solution
Odor	: Odorless
Odor Threshold	: No data available
pH	: 6.8-7.8
Evaporation Rate	: No data available
Melting Point	: No data available
Freezing Point	: No data available
Boiling Point	: 100 °C (212 °F)
Flash Point	: No data available
Auto-ignition Temperature	: No data available
Decomposition Temperature	: No data available
Flammability (solid, gas)	: Not applicable
Lower Flammable Limit	: No data available
Upper Flammable Limit	: No data available
Vapor Pressure	: No data available
Relative Vapor Density at 20°C	: No data available
Relative Density	: No data available
Density	: 1.005 g/ml
Specific Gravity	: No data available
Solubility	: Complete in water.
Partition Coefficient: N-Octanol/Water	: No data available
Viscosity	: No data available

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity:

Hazardous reactions will not occur under normal conditions.

10.2. Chemical Stability:

Stable under recommended handling and storage conditions (see section 7).

10.3. Possibility of Hazardous Reactions:

Hazardous polymerization will not occur.

10.4. Conditions to Avoid:

Direct sunlight, extremely high or low temperatures, and incompatible materials.

10.5. Incompatible Materials:

Strong acids, strong bases, strong oxidizers.

10.6. Hazardous Decomposition Products:

None expected under normal conditions of use.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on Toxicological Effects - Product

Acute Toxicity (Oral): Not classified

Acute Toxicity (Dermal): Not classified

Acute Toxicity (Inhalation): Not classified

LD50 and LC50 Data:

No additional information available

Skin Corrosion/Irritation: Not classified

pH: 6.8-7.8

Eye Damage/Irritation: Not classified

pH: 6.8-7.8

Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

Respiratory or Skin Sensitization: Not classified

Germ Cell Mutagenicity: Not classified

Carcinogenicity: Not classified

Specific Target Organ Toxicity (Repeated Exposure): Not classified

Reproductive Toxicity: Not classified

Specific Target Organ Toxicity (Single Exposure): Not classified

Aspiration Hazard: Not classified

Symptoms/Injuries After Inhalation: Prolonged exposure may cause irritation.

Symptoms/Injuries After Skin Contact: Prolonged exposure may cause skin irritation.

Symptoms/Injuries After Eye Contact: May cause slight irritation to eyes.

Symptoms/Injuries After Ingestion: Ingestion may cause adverse effects.

Chronic Symptoms: None expected under normal conditions of use.

Potential Adverse human health effects and symptoms: Based on available data, the classification criteria are not met.

11.2. Information on Toxicological Effects - Ingredient(s)

LD50 and LC50 Data:

Benzyl alcohol (100-51-6)	
LD50 Oral Rat	1230 mg/kg
LD50 Dermal Rabbit	> 2000 mg/kg
LD50 Intravenous Rat	53 mg/kg
ATE US/CA (dust, mist)	1.50 mg/l/4h
Bumetanide (28395-03-1)	
LD50 Oral Rat	> 6 g/kg
LD50 Oral Mouse	4624 mg/kg

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

Ecology - General: Not classified.

Benzyl alcohol (100-51-6)	
LC50 Fish 1	460 mg/l (Exposure time: 96 h - Species: Pimephales promelas [static])
LC50 Fish 2	10 mg/l (Exposure time: 96 h - Species: Lepomis macrochirus [static])
NOEC Chronic Crustacea	51 mg/l

12.2. Persistence and Degradability

Bumetanide Injection USP	
Persistence and Degradability	Expected to be biodegradable.

12.3. Bioaccumulative Potential

Bumetanide Injection USP	
Bioaccumulative Potential	Not expected to bioaccumulate.
Benzyl alcohol (100-51-6)	
Partition coefficient n-octanol/water (Log Pow)	1.1

12.4. Mobility in Soil

Bumetanide Injection USP	
Ecology - Soil	Leaches if exposed to water.

12.5. Other Adverse Effects

Other Adverse Effects: None known.

Other Information: Avoid release to the environment.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste Treatment Methods: Can be landfilled, when in compliance with local regulations. Incineration is the preferred method for disposal of waste product.

Sewage Disposal Recommendations: Do not dispose of waste into sewer.

Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

Waste Disposal Recommendations: Dispose of contents/container in accordance with local, regional, national, territorial, provincial, and international regulations.

Additional Information: Biologically contaminated materials should be incinerated.

Ecology - Waste Materials: Avoid release to the environment.

SECTION 14: TRANSPORT INFORMATION

The shipping description(s) stated herein were prepared in accordance with certain assumptions at the time the SDS was authored, and can vary based on a number of variables that may or may not have been known at the time the SDS was issued.

14.1. In Accordance with DOT

Not regulated for transport

14.2. In Accordance with IMDG

Not regulated for transport

14.3. In Accordance with IATA

Not regulated for transport

14.4. In Accordance with TDG

Not regulated for transport

SECTION 15: REGULATORY INFORMATION

15.1. US Federal Regulations

Benzyl alcohol (100-51-6)

Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active

15.2. US State Regulations

Benzyl alcohol (100-51-6)

U.S. - Pennsylvania - RTK (Right to Know) List

U.S. - Massachusetts - Right To Know List

15.3. Canadian Regulations

Benzyl alcohol (100-51-6)

Listed on the Canadian DSL (Domestic Substances List)

SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

Date of Preparation : 09/26/2022

or Latest Revision

Other Information : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200 and Canada's Hazardous Products Regulations (HPR) SOR/2015-17.

GHS Full Text Phrases:

Acute Tox. 4 (Inhalation:dust,mist)	Acute toxicity (inhalation:dust,mist) Category 4
Acute Tox. 4 (Oral)	Acute toxicity (oral) Category 4
Aquatic Acute 2	Hazardous to the aquatic environment - Acute Hazard Category 2
Eye Irrit. 2A	Serious eye damage/eye irritation Category 2A
Flam. Liq. 4	Flammable liquids Category 4
Met. Corr. 1	Corrosive to metals Category 1
H227	Combustible liquid
H302	Harmful if swallowed
H319	Causes serious eye irritation
H332	Harmful if inhaled
H401	Toxic to aquatic life

NFPA Health Hazard : 0 - Materials that, under emergency conditions, would offer no hazard beyond that of ordinary combustible materials.


NFPA Fire Hazard : 0 - Materials that will not burn under typical fire conditions, including intrinsically noncombustible materials such as concrete, stone, and sand.

Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

NFPA Reactivity Hazard : 0 - Material that in themselves are normally stable, even under fire conditions.



Bumetanide Injection USP

Safety Data Sheet

According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations And According To The Hazardous Products Regulation (February 11, 2015).

HMIS III Rating

Health : 0 Minimal Hazard - No significant risk to health
Flammability : 0 Minimal Hazard
Physical : 0 Minimal Hazard
Personal protection : B

This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.

NA GHS SDS 2015 (Can, US)